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Background: The WHO classification system for astrocytomas is not considered optimal, mainly because of the
subjective assessment of the histopathological features. Few prognostic variables have been found that stratify the
risk of clinical progression in patients with grade II astrocytoma. For that reason there is a continuous search for
biomarkers that can improve the histopathological diagnosis and prognostication of these tumours.
Aim: This study was designed to investigate the prognostic significance of the proliferative marker Mcm2
(minichromosome maintenance protein 2) in diffuse astrocytomas WHO grade II and correlate the findings with
histopathology, mitoses, and Ki67/MIB-1 immunostaining.
Method: 61 patients with histologically verified grade II astrocytoma (WHO 2007) were investigated. Paraffin
sections were immunostained with anti-Mcm2, and the Mcm2 proliferative index (PI) was determined as the
percentage of immunoreactive tumour cell nuclei.
Results: Mcm2 PI was not associated with any histopathological features but correlated significantly with mitotic
count and Ki67/MIB-1 PI (p<0.05). In the survival analyses Mcm2 showed trends to poorer survival, however,
statistical significance was not achieved in the univariate analyses (p>0.05).
Conclusions: In our hands Mcm2 immunostaining has no advantage over Ki67/MIB-1 in the evaluation of grade II
astrocytomas. Larger studies are needed to fully clarify the prognostic role of this biomarker.
Virtual slides: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/
1715002791944037
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The histopathological criteria for the diagnosis of
astrocytic tumours, are given by the World Health
Organization (WHO) [1]. This classification system is not
optimal, partly due to subjective assessment of the histo-
pathological features. Novel biomarkers are therefore* Correspondence: sverre.torp@ntnu.no
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distribution, and reproduction in any mediumwarranted to improve diagnostic and prognostic accuracy
in such a way that the clinician can work out potentially
more effective treatment plans. Supplemental immunohis-
tochemical and molecular diagnostic analyses are grad-
ually being employed in the diagnosis and evaluation of
astrocytomas. Relevant markers are for instance alter-
ations in pathways of members of the epidermal growth
factor receptor (EGFR) family, methylation status of the
O-6 methyl-guanine-DNA methyltransferase (MGMT)
gene, isocitrate dehydrogenase-1 (IDH1) mutations, and
various proliferation markers [2-5].
Regarding proliferation, it is currently accepted that
the growth rate of a tumour is closely linked to itsCentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
Table 1 Histological features




















Rosenthal fibres 2 3.3
Eosinophilic granular bodies 0 0.0
Microcysts 21 34.4
Myxoid matrix 7 11.5
Microcalcification 3 4.9
Perivascular lymphocytic infiltration 11 18.0
Secondary structures 40 65.6
Subpial 12 19.7
Satellitosis 41 67.2
Angiocentric growth 13 21.3
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erative activity has therefore gained much interest, also
for brain tumours [6-9]. This has traditionally been eval-
uated by counting the number of mitoses. This method
still plays a fundamental role in various histological
grading schemes, including human astrocytomas [10]. It
is, however, encumbered with several disadvantages
including the subjective assessment of mitotic figures
and confusion with pycnotic cells resulting in consider-
able interobserver variation [7].
Due to these limitations, immunohistochemical deter-
mination of proliferative activity has come into daily rou-
tine. The most commonly used antibody is Ki67/MIB-1,
which is an antibody directed against an antigen expressed
during all active phases of the cell cycle [11]. However,
due to a great spread of proliferation indices between dif-
ferent malignancy grades of astrocytic tumours, it is diffi-
cult to establish definitive thresholds values for prognostic
and diagnostic purposes [9,12,13]. Nevertheless, most
studies show that this marker is associated with both
tumour grade and prognosis [9].
There is a continuous search for more specific markers, and
the proliferative-associated minichromosome maintenance
proteins 2–7 (Mcm 2–7) appear promising. They consti-
tute an important role in regulating cell proliferation
through recruiting the replication machinery. Up-
regulation of Mcm expression has been shown in prolifer-
ating cells, indicating potential as a prognostic marker of
malignancy [14]. In fact, it is considered that Mcm-
proteins are more specific than that of Ki67/MIB-1 [15].
Studies on Mcm2 in gliomas are rare. As an example, in a
study on oligodendrogliomas Mcm2 proliferative index
(PI) showed good correlation with mitotic index, Ki67/
MIB-1 PI, and survival [16]. Further, in meningiomas it
was related to increased risk of recurrence [17].
The aim of this study was to investigate the prognos-
tic role of Mcm2 expression in a series of diffuse astro-
cytomas WHO grade II and to correlate it with
histopathological features, mitoses, and Ki67/MIB-1
immunostaining.
Material and methods
This study consists of a series of primary intracranial dif-
fuse astrocytomas WHO grade II in adults (age > 16
years) consecutively operated at St. Olavs Hospital,
Trondheim, Norway, in the time period 1987 to 2007.
Originally the study population constituted a cohort of
109 patients [18,19]. Due to lack of archive material only
61 cases were available for further immunohistochemical
analyses. Patients were collected through search in the
electronic database at the pathology department.
Information about age, gender, tumour location, treat-
ment, symptoms, and performance score was retrieved
from both paper and electronical files at the universityhospital and local hospitals. The cause and date of death
were recorded from the Norwegian Death Registry.
All the routine stained sections were revised, and the
diagnosis was adjusted to the WHO 2007 criteria. Histo-
pathological findings and Ki67/MIB-1 immunostaining
have been published previously (Table 1) [18,19]. Formalin-
fixed and paraffin-embedded sections (61 of the original
109 cases) underwent immunohistochemical analyses using
an automatized immunohistostainer (Dako Techmate 500)
with a standard avidin-biotin-peroxidase technique. The
mouse monoclonal anti-Mcm2 (NCL-MCM2, Novocastra)
was applied with a dilution 1:25. The sections were devel-
oped with diaminobenzidine and counterstained with
haematoxylin. Human tonsils served as positive controls. In
the negative controls the primary antibody was omitted.
Microscopic areas with highest labelling intensity were
chosen for calculations. In each case either at least 1000
Table 2 Descriptive statistics for and Ki67/MIB-1 PI and
Mcm2 PI
Ki67/MIB-1 PI [13] Mcm2 PI
No of cases 60 61
Median 4.6% 2.8%
Range 0.1-13.4% 0-14.5%
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(HPFs) were examined using an eye-grid. The PI was de-
fined as the percentage of immunoreactive tumour cell
nuclei.
The SPSS statistics package 17.0 was used for statis-
tical analyses. Survival curves were calculated according
to the Kaplan-Meier method, and differences in survival
were tested for statistical significance using the log-rank
test and univariate Cox regression. Spearman’s rank cor-
relation was used for investigation of relationship
between the proliferation markers. For analyses of cor-
relation between histological features and Mcm2
Mann–Whitney U-test was used. The kappa statistic
was used to evaluate the interobserver variation.
The Regional Committee for Medical Ethics approved
the study, and the study protocol adhered to guidelines
by Helsinki Convention.
Results
The median age of the 61 astrocytoma patients was 40
years with range 19–74 years. Gender distribution was
24 females and 37 males (ratio 1:1.5). Thirty-eight
(62.3%) patients died during the study period and 45
(73.8%) had relapse recorded. Histological and clinical
characteristics have been previously reported [18,19].
The Ki67/MIB-1 and Mcm2 immunostaining revealed
distinct positive tumour cell nuclei heterogeneously distrib-
uted within the tumour tissue (Figure 1). Glia cells, neurons
and leptomeninges were not immunoreactive. The median
values of Ki67/MIB-1 PI and Mcm2 PI were 4.6% (range
0.1-13.4) and 2.8% (range 0–14.5), respectively (Table 2).
Due to lack of material Ki67/MIB-1 immunostaining was
performed on 60 out of 61 cases. Rank correlation showed
significant correlation between PIs of Ki67/MIB-1 and
Mcm2 immunostainings (p<0.01), also shown in a scatterFigure 1 Image of a Mcm2 immunostaining of a grade II
astrocytomas with positive neoplastic astrocytic cell nuclei
(dark) (40× objective).plot (Figure 2). Significant correlation was also found be-
tween Mcm2 and mitotic count (p = 0.026) (Table 3).
Kappa statistic gave a score of 0.6 indicating moderate
agreement of interobserver variation.
The frequency of histological features is shown in
Table 1. Correlations between histological features and
Mcm2 immunostaining revealed only statistical signifi-
cance with mitoses (p = 0.032) (Table 4).
Using the median value of Mcm2 PI as cut off, mean sur-
vival in the low proliferative group was 92 months com-
pared with 78 months in the high proliferative group.
Regarding overall survival and time to recurrence, no dif-
ference between the two groups was found (overall sur-
vival: log rank test (p = 0.918)) (time to recurrence: log
rank test (p = 0.452)). Neither mitoses nor Ki67/MiB-1 im-
munostaining reached statistical significance in the survival
analyses (mitosis: overall survival: log rank test (p = 0.092);
time to recurrence: log rank test (p = 0.052)) (Ki67/MIB-1:
overall survival: log rank test (p = 0.721); time to recur-
rence: log rank test (p = 0.285)). Kaplan-Meier survival
curves for patients with high and low Mcm2 PIs are shown
in Figure 3. Univariate Cox regression analyses with both
overall survival and time to recurrence as time parameters
were performed, and no significant difference in survival
was found between these groups (Table 5). Even when the
patients were stratified into two groups with PIs of Ki67/
MIB-1 and Mcm2 PIs higher and lower than median
values, no statistically difference in survival was achieved
(p = 0.727).Discussion
Since the WHO classification system for human astrocy-
tomas is not optimal, novel biomarkers are needed.
Antibodies reactive against proliferation-associated anti-
gens have therefore come into focus. This study was
designed to evaluate the prognostic significance of the
proliferation marker Mcm2 in a series of diffuse astrocy-
toma WHO grade II with thorough follow-up, and to
compare its expression with histopathological features,
mitoses, as well as Ki67/MIB-1 immunostaining. We
found that Mcm2 expression correlated well with mi-
totic counts and Ki67/MIB-1 PIs but was not associated
with any specific histopathology. Higher Mcm-2 PIs
showed a trend to poorer survival, but statistical signifi-
cance was not achieved.
Figure 2 Scatterplot of Ki67/MIB-1 PIs versus Mcm2 PIs.
Table 4 Relations between Mcm2 PI and some
histopathological features
Variables p-values
Mcm2 PI and mitoses 0.032
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Mcm2 PIs, and Ki67/MIB-1 PIs found in this study are in
accordance with studies on other human tumours
[16,20-22]. It seems, however, that the range of Mcm2 PIs
varies between types of neoplasms. In our study Mcm2
PIs were lower than Ki67/MIB-1 PIs and comparable with
those in pilocytic astrocytomas, whereas in oligodendro-
gliomas the Mcm2 indices were higher [16,20]. In colorec-
tal cancer Mcm2 was shown to be a stronger indicator of
proliferative cells than Ki67/MIB-1 [23]. The reasons for
these various findings are not obvious, but may be related
to different tumour types, malignancy grades, counting
procedures, type of antibody, and antigen preservation
[8,24]. Further, the immunoprofile of cycling tumour cells
may vary. Mcm2 has been shown to stain cell-cycle initi-
ation and continues to be expressed throughout the cycle
including cells leaving G0 to enter early G1 [25]. In com-
parison, Ki67/MIB-1 immunoreactivity occurs during all
active phases of the cell cycle except G0 [26,27]. Mcm2
may therefore be a biomarker of cells with replication po-
tential (licensed to cycle), and suggestions on potential as
a pre-cancer marker have been made [28].
Our survival analyses did not demonstrate any signifi-
cant prognostic value of Mcm2. Nevertheless, a differ-
ence in survival of 14 months between the patients with
high and low Mcm2 PIs indicates a promising trend.Table 3 Relationship between proliferative markers
Spearman’s rank correlation p-values
Mcm2 PI versus Ki67/MIB-1 PI < 0.01
Mcm2 PI versus mitotic count 0.026Actually, there is scarce knowledge about the value of
Mcm2 in low-grade astrocytomas, so further studies are
highly desired to fully establish its clinical significance in
these tumours. Regarding other neoplasms, the findings
are diverging. In a study on oligodendrogliomas with
both low- and high-grade tumours positive association
with survival was found [16]. In meningiomas high
Mcm2 PI was associated with early recurrence [17]. On
the contrary, no correlation to survival was established
in a series of pilocytic astrocytomas [20].
Beyond the correlation with mitoses, Mcm2 was not as-
sociated with any other histological features related to ma-
lignancy in our series of astrocytomas, such as cell density,
apoptoses, and atypia. In contrast, in a previous study
Ki67/MIB-1 showed positive correlation with apoptoses,
cellularity, and atypia [14]. We have no obvious reasons for
this difference, but it may be related to lower values of
Mcm2 in grade II due to earlier stage in the gliomagenesis.
Due to a limited number of patients and the well-
known heterogeneity of astrocytic tumours, our data must
be interpreted with discretion. The wide range of Mcm2Mcm2 PI and apoptoses 0.302
Mcm2 PI and cell density 0.974
Mcm2 PI and atypia 0.395
Mcm2 PI and microcysts 0.267
Mcm2 PI and secondary structures 0.952
Figure 3 Kaplan-Meier survival curves for patients with
different Mcm2 PIs (cut off at median value) (overall survival,
log rank test p = 0.918).
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mas of various malignancy grades comparable with that of
Ki67/MIB-1 immunostaining [9]. It seems as if this
phenomenon is a rather typical trait for proliferation
markers reducing their utility in the routine diagnostics.
Additionally, immunohistochemistry has its intrinsic ad-
versity, such as the definition of immunoreactive cells
(non-neoplastic and neoplastic cells, threshold values
etc.), and several studies have poor definition of the quan-
titation procedures or reproducibility [7,8,29,30]. On the
other hand, reliable follow-up data, combination of two
proliferation markers, and the attempt to compensate for
intraobserver reliability through Kappa statistic, are some
of the strengths of this study.Table 5 Prognostic factors: survival determined by
univariate Cox regression analyses including both overall
survival and time to recurrence
Factors p values Significance
Overall survival
- Mcm2 PI 0.367 NS
- Ki67/MIB-1 PI 0.239 NS
- Mitotic count 0.099 NS
Time to recurrence
- Mcm2 PI 0.407 NS
- Ki67/MIB-1 PI 0.516 NS
- Mitotic count 0.057 NSIn conclusion, Mcm2 immunostaining correlates well
with mitotic activity and Ki67/MIB-1 expression.
However, none of these were shown not to have any sig-
nificant influence on patient outcome, even if the
markers were combined. Accordingly, Mcm2 does not
seem to have any advantages over Ki67/MIB-1 in the
evaluation of the prognosis of grade II astrocytomas.
However, larger studies are necessary to clarify the defin-
ite role of Mcm2 in these tumours.
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